{"entity":{"id":"nct05933265","kind":"trial","name":"Study of LP-184 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting.","summary":"Study of LP-184 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05933265 by Lantern Pharma Inc., with 64 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2026-07-28. Interventions recorded: LP-184, Olaparib and Nivolumab & Ipilimumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05933265","url":"https://clinicaltrials.gov/study/NCT05933265"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","nsclc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib","ipilimumab","nivolumab","lp-184"],"companies":["lantern-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05933265-invest-new-drugs-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05933265","phase":"1/2","setting":"A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Lantern Pharma Inc.","started":"2023-06-09","startedType":"actual","enrolled":64,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05933265/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","route":"/companies/lantern-pharma/"}],"paper":[{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/"}]}}